期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 109, 期 24, 页码 9499-9504出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1202924109
关键词
neutralizing determinant; protective determinant; antigen-antibody complex; type I' beta-turn
资金
- National Institutes of Health (NIH) [HHSN272200900041C, AI80916, AI79031, AI71084, AI84817]
- The Skaggs Institute
- National Cancer Institute [Y1-CO-1020]
- National Institute of General Medical Sciences (NIGMS) [Y1-GM-1104]
- US Department of Energy, Basic Energy Sciences, and Office of Science [DE-AC02-06CH11357]
- The Scripps Research Institute [21617]
Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is genetically diverse, and therefore a broadly effective vaccine must target conserved T- and B-cell epitopes of the virus. Human mAb HCV1 has broad neutralizing activity against HCV isolates from at least four major genotypes and protects in the chimpanzee model from primary HCV challenge. The antibody targets a conserved antigenic site (residues 412-423) on the virus E2 envelope glycoprotein. Two crystal structures of HCV1 Fab in complex with an epitope peptide at 1.8-angstrom resolution reveal that the epitope is a beta-hairpin displaying a hydrophilic face and a hydrophobic face on opposing sides of the hairpin. The antibody predominantly interacts with E2 residues Leu(413) and Trp(420) on the hydrophobic face of the epitope, thus providing an explanation for how HCV isolates bearing mutations at Asn(415) on the same binding face escape neutralization by this antibody. The results provide structural information for a neutralizing epitope on the HCV E2 glycoprotein and should help guide rational design of HCV immunogens to elicit similar broadly neutralizing antibodies through vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据